Form 4: Atlas Venture Funds Sell Dyne Therapeutics Shares Under 10b5-1 Plans

Atlas Venture Opportunity Funds I and II sold shares of Dyne Therapeutics (DYN) at $30.05 per share under pre-arranged Rule 10b5-1 trading plans.

Summary

• Atlas Venture Opportunity Fund I, L.P. sold 29,435 shares of Dyne Therapeutics (DYN) common stock on March 1, 2024, at a price of $30.05 per share.
• Following the transaction, Atlas Venture Opportunity Fund I, L.P. directly owns 1,458,691 shares.
• Atlas Venture Opportunity Fund II, L.P. sold 17,099 shares of Dyne Therapeutics common stock on March 1, 2024, at a price of $30.05 per share.
• Following the transaction, Atlas Venture Opportunity Fund II, L.P. indirectly owns 847,388 shares.
• These transactions were executed under Rule 10b5-1 trading plans adopted on January 10, 2024.
• The reporting entities include Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, L.P., and Atlas Venture Associates Opportunity II, LLC.

Sentiment

Score: 5

Explanation: The document reflects routine transactions under a pre-existing trading plan, indicating a neutral sentiment. There is no information to suggest a positive or negative outlook.

Industry Context

This Form 4 filing indicates activity by a major shareholder, Atlas Venture, in Dyne Therapeutics. Monitoring such filings provides insights into investor sentiment and potential future stock performance.

Stakeholder Impact

• The sale of shares by a significant shareholder like Atlas Venture could potentially influence investor perception and Dyne Therapeutics' stock price.

Key Dates